Free Trial

Tandem Diabetes Care (TNDM) 10K Form and Latest SEC Filings 2026

Tandem Diabetes Care logo
$15.88 -2.59 (-14.00%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Tandem Diabetes Care SEC Filings & Recent Activity

Tandem Diabetes Care (NASDAQ:TNDM) has submitted 608+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Tandem Diabetes Care's financial statements. The most recent filing was a Form 10-Q submitted on May 7, 2026.

Form 4
TANDEM DIABETES CARE INC Reports Ownership Change on Apr. 17, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Tandem Diabetes Care Files Current Report on May. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Tandem Diabetes Care Files Quarterly Report on May. 7, 2026

The 10-Q contains Tandem Diabetes Care's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Tandem Diabetes Care SEC Filing History

Browse Tandem Diabetes Care's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/07/2026 3:02 PM
Tandem Diabetes Care (1438133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2026 3:06 PM
Tandem Diabetes Care (1438133) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/05/2026 9:48 AM
Tandem Diabetes Care (1438133) Subject
Voya Financial, Inc. (1535929) Filed by
Form SCHEDULE 13G
04/29/2026 2:21 PM
Tandem Diabetes Care (1438133) Subject
VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by
Form SCHEDULE 13G
04/17/2026 3:10 PM
Kyrillos Jean-Claude (1804186) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 3:04 PM
Tandem Diabetes Care (1438133) Filer
Form ARS
04/07/2026 3:23 PM
Tandem Diabetes Care (1438133) Filer
Form DEF 14A
04/07/2026 3:23 PM
Tandem Diabetes Care (1438133) Filer
Form DEFA14A
03/27/2026 12:18 PM
Tandem Diabetes Care (1438133) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/17/2026 3:38 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/09/2026 3:27 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 3:29 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2026 3:33 PM
Hansen Shannon Marie (1908267) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:34 PM
Tandem Diabetes Care (1438133) Issuer
Vosseller Leigh (1726322) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:34 PM
Sheridan John F (1365369) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:36 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:36 PM
Morrison Susan (1582970) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:37 PM
Gasser Elizabeth Anne (1866283) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:37 PM
Carpenter Rick (1513889) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:09 PM
Tandem Diabetes Care (1438133) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
01/20/2026 3:09 PM
Kyrillos Jean-Claude (1804186) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:29 PM
Tandem Diabetes Care (1438133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/17/2025 3:01 PM
Carpenter Rick (1513889) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 3:02 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 3:02 PM
Gasser Elizabeth Anne (1866283) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:06 PM
Hansen Shannon Marie (1908267) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:06 PM
Tandem Diabetes Care (1438133) Issuer
Vosseller Leigh (1726322) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:06 PM
Kyrillos Jean-Claude (1804186) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:06 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:06 PM
Carpenter Rick (1513889) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:06 PM
Gasser Elizabeth Anne (1866283) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:07 PM
Sheridan John F (1365369) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:07 PM
Morrison Susan (1582970) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 8:01 AM
ArrowMark Colorado Holdings LLC (1483859) Filed by
Tandem Diabetes Care (1438133) Subject
Form SCHEDULE 13G
11/12/2025 8:02 AM
Tandem Diabetes Care (1438133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2025 3:15 PM
Tandem Diabetes Care (1438133) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 3:09 PM
Tandem Diabetes Care (1438133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2025 3:21 PM
Kyrillos Jean-Claude (1804186) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2025 3:47 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2025 3:47 PM
Carpenter Rick (1513889) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 5:14 PM
Gasser Elizabeth Anne (1866283) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 5:14 PM
Hansen Shannon Marie (1908267) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 5:14 PM
Tandem Diabetes Care (1438133) Issuer
Vosseller Leigh (1726322) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 5:14 PM
Carpenter Rick (1513889) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 5:14 PM
Sheridan John F (1365369) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 5:14 PM
Morrison Susan (1582970) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 5:14 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/11/2025 5:15 PM
Sheridan John F (1365369) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/11/2025 4:18 PM
Tandem Diabetes Care (1438133) Issuer
Vosseller Leigh (1726322) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2025 3:23 PM
Tandem Diabetes Care (1438133) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/17/2025 3:11 PM
Kyrillos Jean-Claude (1804186) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 4:30 PM
Tandem Diabetes Care (1438133) Issuer
Vosseller Leigh (1726322) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 4:20 PM
Carpenter Rick (1513889) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 4:22 PM
Gasser Elizabeth Anne (1866283) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 4:24 PM
Sheridan John F (1365369) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 4:24 PM
Hansen Shannon Marie (1908267) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 4:25 PM
Morrison Susan (1582970) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 4:25 PM
Kyrillos Jean-Claude (1804186) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 4:26 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 5:05 PM
Tandem Diabetes Care (1438133) Issuer
Vosseller Leigh (1726322) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 5:05 PM
Kyrillos Jean-Claude (1804186) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 5:06 PM
Sheridan John F (1365369) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 5:06 PM
Carpenter Rick (1513889) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 5:06 PM
Gasser Elizabeth Anne (1866283) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 5:06 PM
Morrison Susan (1582970) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 5:06 PM
Novara Mark David (2000342) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 5:07 PM
Hansen Shannon Marie (1908267) Reporting
Tandem Diabetes Care (1438133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Tandem Diabetes Care SEC Filings - Frequently Asked Questions

Tandem Diabetes Care (TNDM) has submitted 608+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Tandem Diabetes Care's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Tandem Diabetes Care's financial statements page.

The most recent filing was a Form 10-Q submitted on May 7, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:TNDM) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners